Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer

Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

(2017) R. A. Burger et al.   JOURNAL OF CLINICAL ONCOLOGY

Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.

(2017) P. Sabbatini et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer

(2010) N Leffers et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study

(2010) Shimon Slavin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Consolidation Therapy in Ovarian Cancer

(2010) Paul Sabbatini   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

(2010) S Bafna et al.   ONCOGENE

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

(2009) Maurie Markman et al.   GYNECOLOGIC ONCOLOGY

Anti-idiotypic Immunotherapy in Follicular Lymphoma Patients

(2009) Rosa Yáñez et al.   JOURNAL OF IMMUNOTHERAPY

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

(2008) Jonathan Berek et al.   JOURNAL OF CLINICAL ONCOLOGY

CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer

(2008) Jonathan S. Berek et al.   JOURNAL OF IMMUNOTHERAPY